Several clinical trials using IL-7 are currently underway in cancer, HIV, HBV and HCV infections to remediate disease-associated immune deficits and our results in mice suggest that increasing IL-7 levels may also affect fat mass development and insulin sensitivity in the IL-7-treated patients. This evidence concerns the gene INS and cancer.